Esperion Therapeutics Inc (NASDAQ:ESPR) was the recipient of some unusual options trading on Thursday. Stock traders purchased 1,070 put options on the company. This is an increase of approximately 1,254% compared to the average volume of 79 put options.
ESPR has been the topic of several recent analyst reports. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 29th. BidaskClub lowered Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 31st. Cowen reiterated a “buy” rating and issued a $80.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, July 18th. Stifel Nicolaus cut their price objective on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. Finally, Goldman Sachs Group upgraded Esperion Therapeutics from a “sell” rating to a “neutral” rating and cut their price objective for the company from $55.00 to $45.00 in a research report on Monday, September 16th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $71.60.
Shares of ESPR stock traded up $1.41 on Friday, reaching $38.41. 453,069 shares of the stock were exchanged, compared to its average volume of 350,740. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65. Esperion Therapeutics has a one year low of $33.13 and a one year high of $60.99. The stock has a 50 day moving average price of $36.63 and a 200 day moving average price of $42.85. The stock has a market cap of $961.84 million, a PE ratio of -5.09 and a beta of 1.89.
In other news, major shareholder Target N. V. Biotech acquired 80,000 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were bought at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the acquisition, the insider now owns 3,652,964 shares of the company’s stock, valued at $123,397,123.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Timothy M. Mayleben acquired 2,500 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were purchased at an average cost of $35.25 per share, for a total transaction of $88,125.00. Following the acquisition, the chief executive officer now directly owns 76,015 shares in the company, valued at approximately $2,679,528.75. The disclosure for this purchase can be found here. Insiders acquired a total of 142,500 shares of company stock worth $5,291,825 in the last ninety days. Insiders own 7.70% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Aperio Group LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth $29,000. Russell Investments Group Ltd. acquired a new position in Esperion Therapeutics in the second quarter valued at about $32,000. Bank of Montreal Can grew its stake in Esperion Therapeutics by 364.5% in the second quarter. Bank of Montreal Can now owns 2,671 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 2,096 shares during the period. Royal Bank of Canada grew its stake in Esperion Therapeutics by 38.1% in the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 811 shares during the period. Finally, Marshall Wace North America L.P. acquired a new position in Esperion Therapeutics in the first quarter valued at about $164,000.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More: What is Call Option Volume?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.